Neurology

Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study

In “Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study,” Bar-Or et al. demonstrated a significant reduction in the number of new brain lesions in patients who were given ofatumumab compared with those who received placebo. However, Dr. Kearney notes that comparing ofatumumab to placebo, rather than a disease-modifying therapy, could have artificially inflated the benefit of ofatumumab.

Source link




Related posts

Accurate etiology diagnosis in patients with stroke and atrial fibrillation: A role for brain natriuretic peptide

Newsemia

Clinical Reasoning: West syndrome, pontocerebellar hypoplasia, and hypomyelination in a 6-month-old boy

Newsemia

TIME: Humans are hardwired to tell history in stories. Neuroscience tells us why we get them wrong

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy